Legal entity
Eli Lilly and Company is most often covered alongside FDA, which appears in 1 of these 2 stories. Each story carries 13 original sources on average, compared with 3.7 for the broader beat in this window. Across a 131-day span, the pace is roughly 0.1 stories per week.
Last mentioned: 3h ago
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Eli Lilly and Company is most often covered alongside FDA, which appears in 1 of these 2 stories. Each story carries 13 original sources on average, compared with 3.7 for the broader beat in this window. Across a 131-day span, the pace is roughly 0.1 stories per week. court-decisions accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. At 7, the average consequence score sits above the same-window beat average of 6.5. Eli Lilly and Company appears in 2 tracked Legal stories published from March 13, 2026 through July 21, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 996 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Eli Lilly and Company. Shared-story counts are live from our verified record — not editorial picks.
Lawsuit Filed
Novo Nordisk sues Eli Lilly in the U.S. District Court for the District of New Jersey, alleging false advertising and unfair competition under the Lanham Act.
Impurity Warning
Lilly issues formal warning after testing reveals impurities in compounded samples.
FDA Approves Wegovy 7.2 mg
Novo Nordisk receives U.S. approval for a higher-dose semaglutide injection for obesity, backed by the STEP UP trial showing 19% average weight loss.
Compounding Surge
Shortage status triggers Section 503B exemptions, allowing pharmacies to mass-produce compounded versions.
Zepbound Approval
Tirzepatide approved for chronic weight management, exacerbating supply shortages.
Mounjaro FDA Approval
FDA approves tirzepatide for type 2 diabetes, leading to immediate high demand.
Novo Nordisk alleges Lanham Act violations; case tests whether outdated comparisons in DTC ads constitute false advertising, with potential precedent for pharma.
Source: rttnews.com · finanznachrichten.de
Eli Lilly has issued a formal warning regarding discovered impurities in compounded versions of its blockbuster weight-loss medication, tirzepatide. This development marks a significant escalation in the ongoing regulatory and legal conflict between pharmaceutical giants and the compounding industry over safety standards and patent enforcement.
Source: kiss1067.iheart.com · power1051.iheart.com
Eli Lilly and Company is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
